Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure

• Main Authors: April Armstrong (Author), Carle Paul (Author), Luis Puig (Author), Wolf Henning Boehncke (Author), Michael Freeman (Author), Hideshi Torii (Author), Kim Papp (Author), Christopher E. M. Griffiths (Author), Andrew Blauvelt (Author), Kristian Reich (Author), Melinda Gooderham (Author), Tadashi Terui (Author), Lisa Renda (Author), Noah Agada (Author), Wen Xu (Author), Gaia Gallo (Author), Mark G. Lebwohl (Author)
• Format: Book
• Published: Adis, Springer Healthcare, 2019-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Introduction Long-term safety data are critical for evaluating therapies for psoriasis. Ixekizumab has demonstrated efficacy and is well tolerated for the treatment of moderate-to-severe plaque psoriasis. We examined the safety and tolerability of up to 5 years of ixekizumab therapy in pati...